VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
2.920
+1.220 (71.76%)
At close: Jan 30, 2026, 4:00 PM EST
3.040
+0.120 (4.11%)
After-hours: Jan 30, 2026, 7:59 PM EST
VivoSim Labs Employees
As of September 30, 2025, VivoSim Labs had 13 total employees, including 5 full-time and 8 part-time employees. The number of employees decreased by 6 or -31.58% compared to the same quarter last year.
Employees
13
Change
-6
Growth
-31.58%
Revenue / Employee
$10,769
Profits / Employee
-$152,538
Market Cap
7.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 13 | -7 | -35.00% | 13 | 0 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Dec 31, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Sep 30, 2024 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2024 | 20 | -3 | -13.04% | 20 | 0 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Dec 31, 2023 | 18 | -2 | -10.00% | 18 | 0 |
| Sep 30, 2023 | 23 | 3 | 15.00% | 23 | 0 |
| Jun 30, 2023 | 23 | 4 | 21.05% | 23 | 0 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Dec 31, 2022 | 20 | 8 | 66.67% | 20 | 0 |
| Sep 30, 2022 | 20 | 9 | 81.82% | 20 | 0 |
| Jun 30, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Dec 31, 2021 | 12 | 5 | 71.43% | 12 | 0 |
| Sep 30, 2021 | 11 | 5 | 83.33% | 11 | 0 |
| Jun 30, 2021 | 9 | 3 | 50.00% | 9 | 0 |
| Mar 31, 2021 | 9 | 3 | 50.00% | 4 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| GeoVax Labs | 17 |
| Genprex | 15 |
| Indaptus Therapeutics | 7 |
| Galmed Pharmaceuticals | 6 |
| Matinas BioPharma Holdings | 3 |
| Silo Pharma | 3 |
| PMGC Holdings | 3 |
| Propanc Biopharma | 2 |
VIVS News
- 1 day ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire
- 25 days ago - VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer - GlobeNewsWire
- 6 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 9 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 9 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 9 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 10 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 10 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire